Arvinas (NasdaqGS:ARVN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker14Thank you. I will now turn the call over to Jeff Boyle, Head of Investor Relations. Jeff, you may begin.Speaker9Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release with our fourth quarter and full year 2025 financial results, which is available in the investor and media section of our website at arvinas.com. Joining us on the call today, we have Randy Teel, our President and CEO, N ...

Beam Therapeutics (NasdaqGS:BEAM) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker14Good morning, and welcome to Beam Therapeutics conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at Beam's request. I would now like to turn the call over to Holly Manning, Vice President of Investor Relations and External Communications. Please go ahead.Speaker9Thank you, operator. G ...

[https://securitiesclasslaw.com/securities/uniqure-loss-submission-form/?id=183769&from=4]NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of QURE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 13, 2026. There is no cost or obligation to you to participate in this case.WHY GROSS LAW FIRM? The Gross Law Fi ...

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration on January 12, 2 ...

HILLSBORO, Ore., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shorepower Technologies, Inc. (OTC: SPEV) ("Shorepower" or the "Company") today announced that it has entered into an Agreement and Plan of Merger dated February 17, 2026, with Aeternum Health LLC ("Aeternum Health"), pursuant to which Aeternum Health will merge with and into Shorepower, with Shorepower continuing as the surviving entity.Upon completion of the merger, the Company intends to transition its strategic focus from transportation electrification ...

GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused ...

Q4 & FY 2025 Financial Results & Business Update February 24, 2026 Copyright © 2026 Harmony Biosciences. All rights reserved. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations ...

Kyntra Bio Inc. (NASDAQ:KYNB) , formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating metastatic castration-resistant prostate cancer.Prostate Cancer Data Shows Response Rate Of 21%The data presented showed a median radiographic progression-free survival (rPFS) of 10.1 months in patients who had progressed on only one prior androgen receptor pathway inhibitor (ARPI).The study included ...

GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- The law firm of [Robbins Geller Rudman & Dowd LLP] is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL).If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who su ...

Vancouver, British Columbia – TheNewswire - February 24, 2026 – MindBio Therapeutics Corp. (CSE: MBIO | Frankfurt: WF6 | OTCQB: MBQIF) (“MindBio” or the “Company”), a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection, today announced the appointment of Felipe Leyton — one of South America’s most influential drug and alcohol policy architects and a recognized mining industry safety authority — to lead commercialization across the South Ame ...